Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Killed *Escherichia coli* K-12 refers to an inactivated preparation of the *Escherichia coli* K-12 strain, a widely used laboratory bacterium. This preparation is primarily investigated in research settings, particularly for its potential as a vaccine candidate. When used as a vaccine, its mechanism of action involves presenting bacterial antigens to the host's immune system, thereby stimulating a humoral and/or cellular immune response to protect against specific pathogens or conditions. Studies have explored its use in developing vaccines against influenza and extraintestinal pathogenic *E. coli* (ExPEC) infections. The use of heat-killed *E. coli* K12 for oral administration has been proven safe in clinical trials.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on killed escherichia coli k12.